PEA benefits for pain management are unquestionable.
Whether it’s neck pain, chronic low back pain, or knee pain, more than 20 percent of American adults experience chronic pain daily. Over 30 million people take non-steroidal anti-inflammatory drugs like ibuprofen, aspirin, naproxen, etc., or NSAIDs daily. However, these drugs can cause bothersome health problems, such as nausea, heartburn, and gastrointestinal distress. Prescription opioids like hydrocodone are sometimes used to treat severe pain but can be addictive. In addition, these drugs may cause a few side effects, such as insomnia, headache, constipation, dry mouth, and chest pain, along with the potential for opioid withdrawal symptoms.
Currently, the natural compound Pea palmitoylethanolamide can potentially reduce or even eliminate chronic pain in many patients. A study in Neurological Disorders of the Central Nervous System – Drug Targets found that when people took a daily supplement of 600 mg of Palmitoylethanolamide powder, 88% reported being able to move around comfortably. 82% reported a 50% or greater reduction in pain severity within three weeks. These results are comparable to those for over-the-counter and prescription pain relievers. Pea palmitoylethanolamid’s benefits were even significantly better than ibuprofen in one study. And it doesn’t have the side effects of over-the-counter and prescription drugs.
Alpha-palmitoylethanolamide is an endogenous fatty acid amide and a homolog of the endocannabinoid anandamide (AEA). They belong to a class of lipid mediators, the N-acylethanolamine superfamily. PEA has been reported to inhibit the release of proinflammatory mediators from activated mast cells and reduce mast cell recruitment and activation at sites of nerve injury. These events are associated with anti-allodynic and anti-hyperalgesic effects in neuropathic models. Furthermore, PEA treatment inhibited microglial activation and mast cell recruitment to the spinal cord following peripheral nerve injury and spinal cord neuroinflammation or spinal cord injury. At the same time, its effects on chronic and neuropathic pain symptoms have been demonstrated in many clinical situations.
Many plants and animals naturally contain palmitoylethanolamide powder, like soy lecithin, beans, egg yolks, peanuts, alfalfa, milk, and other foods. However, palmitoylethanolamide is used in much larger doses than food for pain control. Generally speaking, palmitoylethanolamide dosage is 150-600 mg. Supplement once or twice daily. If supplemented only from food, a person would have to consume one pound of soy lecithin or one hundred thousand peanuts per day.
PEA supports a healthy inflammatory response.
Gencor reports that its palmitoylethanolamide PEA ingredient called Levagen+ is used in more topical and cosmeceutical products, including a recent application in the LYMA skincare line. This ingredient is designed to support a healthy inflammatory response and prevent damage caused by oxidative stress.
Premium brands such as LYMA Skincare have added Levagen+ to their breakthrough skincare collections to improve elasticity, reduce redness, and protect against damage caused by oxidative stress. It also helps slow immune dysregulation in the skin through the skin’s extracellular matrix (ECM). The company explains that as an endogenous fatty acid amide, it is naturally produced by the body in response to injury and stress. However, the body’s naturally produced PEA decreases with age. It can lead to imbalanced levels of inflammation and a weakened immune system. Levagen+ helps target inflammation, which is the chronic, low-grade inflammation associated with age-related skin changes. Common symptoms are uneven skin tone, dullness, fine lines, and dehydration.
Levagen+ is made using Pharmako Biotechnologies’ LipiSperse delivery technology. It is suitable for gels, creams, effervescents, and powders.
PEA controls symptoms of diabetic peripheral neuropathy.
PEA is an amide with an “autologous local inflammatory antagonism” effect and can protect against neurodegeneration caused by mast cell degranulation. PEA added to alpha-lipoic acid has been successfully used to treat neuropathic pain. However, no data is specific to diabetic peripheral neuropathy (DPN).
In a pilot longitudinal observational study, clinical and biochemical data were retrospectively retrieved for 98 consecutive subjects with type 1 diabetes (T1D) who underwent DPN symptom assessment between January and July 2017. DPN symptoms were assessed with the Neuropathy Symptom Score (NSS). Follow-up data were retrieved for patients with NSS ≥3 who received ALA 600 mg/day ± PEA 600 mg/day or no treatment.
RESULTS: NSS ≥3 in 34 (34.7%) subjects. Among them, 17 cases received ALA ± PEA treatment (9 cases received ALA monotherapy, and 8 cases used PEA in addition to ALA). Seventeen cases did not receive treatment. After a mean follow-up of 8.1±3.4 months, 76.5% of untreated subjects had NSS ≥ 3. This compared to 29.4% of treated subjects (p<0.01). The percentage of subjects with NSS ≥3 did not differ between subjects treated with ALA and those treated with ALA+PEA (p=0.62). Mean time to symptom resolution (NSS<3) was lower in subjects treated with ALA+PEA than in subjects treated with ALA monotherapy (14.0±8.6 days vs. 25.0±9.1 days, p<0.05). Among treated subjects, baseline HDL-cholesterol was inversely correlated with time to resolution of symptoms (p=0.026)
It can be seen that the addition of PEA to ALA accelerates the remission of neuropathic symptoms in T1D subjects with DPN. This study also suggests that HDL-cholesterol may be a biomarker of treatment response to ALA ± PEA.
PEA Palmitoylethanolamide has proven efficacy as a pain treatment ingredient. And no obvious side effects. In addition, its anti-inflammatory effect is also used in some medicinal skin care products. PEA with alpha lipoic acid powder can control diabetic peripheral neuropathy and is also supported by data. It is believed that in future applications, the research and application of this ingredient will become more mature. As an FDA-registered raw ingredients supplier, Nutri Avenue offers bulk PEA Palmitoylethanolamide powder at wholesale price to support various studies and related product launches.